Oliver Dorigo, MD, PhD, Director of the Stanford Gynecologic Oncology Clinical Care Program and Director of Stanford Obstetrics and Gynecology’s Division of Gynecologic Oncology provided an introduction to clinical trials for ovarian cancer patients. Dr. Dorigo discussed what clinical trials are, why they are important and how they work, the pros and cons of enrolling in trials, and things to think about and questions to ask your doctor about clinical trials. He also took questions at the end. Watch the ovarian cancer clinical trials webinar.
Dr. Dorigo received his medical degree from the University of Heidelberg Medical School in Germany, followed by residency training in Obstetrics and Gynecology at the University of Munich, Germany, He joined the Cancer Gene Therapy at the Sidney Kimmel Cancer Center in San Diego, CA, and participated in early clinical trials using gene therapy for cancer disease. Dr. Dorigo subsequently moved to the UCLA David Geffen School of Medicine, Los Angeles, CA, and completed his residency in Obstetrics and Gynecology. He then joined a PhD program at UCLA, and earned his degree in Molecular Biology while working on the development of a new gene transfer system. His research has been published in various scientific journals, including Journal of Virology, Proceedings of the National Academy of Sciences, Journal of Immunology, Cancer Research and Cancer Gene Therapy.
Following his PhD basic science training, Dr. Dorigo completed a clinical fellowship in Gynecologic Oncology at UCLA /Cedars Sinai Medical Center. He subsequently joined the Division of Gynecologic Oncology in the UCLA Department of Obstetrics and Gynecology. Dr. Dorigo joined Stanford University as the Director of Gynecologic Oncology, as of April 2013. His clinical focus is the treatment of patients with gynecologic cancers, including ovarian, cervical, endometrial, vaginal and vulva cancer. In his surgical practice, Dr. Dorigo is emphasizing the use of minimal invasive technologies in particular laparoscopic and robotic surgery.
In addition to his clinical practice, Dr. Dorigo is committed to the development of innovative new therapies for patient with gynecologic malignancies. These efforts are focused both on research in the laboratory, and the testing of new drugs in particular molecular therapies and immunotherapy in clinical trials at the Stanford Women’s Cancer Center.
